Search Results for keywords:"misleading claims"

The Federal Trade Commission (FTC) has issued a proposed consent order regarding IntelliVision Technologies Corp., which will settle allegations of misleading claims made about their facial recognition software. The FTC accused IntelliVision of falsely claiming high accuracy rates and unbiased performance across genders and races, as well as their software’s robustness against spoofing attempts. This Proposed Order includes measures to prevent similar misleading claims in the future and will remain open for public comment until January 6, 2025. Furthermore, the company is required to ensure their claims are supported by competent and reliable testing, and they must comply with specific accuracy and reporting requirements outlined by the FTC.

The Food and Drug Administration (FDA) has issued an order permanently banning John Warrington Kosolcharoen from working with companies that have approved or pending drug product applications. This decision resulted from his felony conviction for fraudulently selling an unapproved stem cell product, ReGen, and making misleading claims about its safety and effectiveness. Mr. Kosolcharoen was given the chance to challenge the debarment but did not respond in the provided timeframe, leading to a waiver of his right to a hearing on the decision. During his debarment, any business that employs him for related services could also face penalties.